Home Health Osteoporosis Pipeline Review, Therapeutics Development and Vaccine H1 2017

Osteoporosis Pipeline Review, Therapeutics Development and Vaccine H1 2017

7
SHARE

The research report “Osteoporosis – Pipeline Review, H1 2017” provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Complete research report on H1 2017 pipeline review of Osteoporosis with 87 market data tables and 11 figures, spread across 247 pages is available at https://www.marketinsightsreports.com/reports/051811118/osteoporosis-pipeline-review-h1-2017

Companies Involved in Therapeutics Development are Addex Therapeutics Ltd, Alize Pharma SAS, Alvogen Korea Co Ltd, Amgen Inc, Amura Holdings Ltd, BiologicsMD Inc, Bone Biologics Corp, Bristol-Myers Squibb Company, Cellmid Ltd, ChoDang Pharm Co Ltd, Chugai Pharmaceutical Co Ltd, Corium International Inc, Critical Pharmaceuticals Ltd, Daiichi Sankyo Company Ltd, ElexoPharm GmbH, EndoCeutics Inc, Entera Bio Ltd, Enteris BioPharma Inc, Enzo Biochem Inc, F. Hoffmann-La Roche Ltd, Gador SA, GL Pharm Tech Corp, Glide Pharmaceutical Technologies Ltd, Hanmi Pharmaceuticals Co Ltd, Haoma Medica Ltd, Immunovo BV, Immunwork Inc, Intas Pharmaceuticals Ltd, Ipsen SA, Kaken Pharmaceutical Co Ltd, Lead Discovery Center GmbH, Ligand Pharmaceuticals Inc, Lotus Pharmaceutical Co Ltd, Lupin Ltd, Merck & Co Inc, Mereo Biopharma Group Plc, NIBEC, Omeros Corp, Oncobiologics Inc, Osteologix Holdings Plc, Paras Biopharmaceuticals Finland Oy, Pfenex Inc, PhytoHealth Corp, R Pharm, Ribomic Inc, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, Shin Poong PharmCo Ltd, Sinil Pharmaceutical Co Ltd, Stelis Biopharma Pvt Ltd, Sumitomo Dainippon Pharma Co Ltd, Terpenoid Therapeutics Inc, TSH Biopharm Corporation Ltd, Uni-Bio Science Group Ltd, Viking Therapeutics Inc, Wroclawskie Centrum Badan EIT+ Sp z oo, Yooyoung Pharm Co Ltd and Zydus Cadila Healthcare Ltd.

Any questions? Feel free to reach us at https://www.marketinsightsreports.com/reports/051811118/osteoporosis-pipeline-review-h1-2017/inquiry

Drug Profiles discussed in this research are (acolbifene hydrochloride + prasterone), (cholecalciferol + raloxifene), (cholecalciferol + risedronate sodium), 2-AMD, 3D-QM, 3D-QMS, abaloparatide, ADX-68693, AKR-215, AKR-308, alendronate sodium, AM-3701, ARC-205, BCD-700, BMD-1111, BMS-777607, BPS-804, calcitonin DR, CD-030, CDR-914K058, CDRI-99/373, CH-5036249, denosumab, denosumab biosimilar, Drugs to Chelate Iron for Bone Degeneration, Postmenopausal Osteoporosis and Thalassemia, Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders, DS-1501, eldecalcitol, Eu-232, Ewha-18278, genipin, HCP-1405, HCP-1604, IG-8801, IHBD-1, IPS-02001, KAL-671, KKM-0805, KKM-0902, KN-012, lasofoxifene tartrate, MAb-4, MDY-1001, Monoclonal Antibody to Inhibit Midkine for Bone Fractures, Monoclonal Antibody to Inhibit Sclerostin for Osteoporosis, NBS-101, NEP-28, OGX-528, OXY-133, OXY-149, OXY-153, PF-708, PHN-031, Protein to Antagonize PPAR Gamma-2 for Rheumatoid Arthritis, Obesity and Osteoporosis, Proteins to Inhibit RANKL for Oncology and Osteoporosis, R-Spondin 1, RBM-007, Recombinant Peptide to Agonize PTH1R for Osteoporosis, Recombinant Protein 1 for Osteoporosis and Rheumatoid Arthritis, Recombinant Protein 2 for Osteoporosis and Rheumatoid Arthritis, Recombinant Protein 3 for Osteoporosis and Rheumatoid Arthritis, Recombinant Protein for Bone Disorders and Osteoporosis, Recombinant Protein for Osteoporosis and Osteoarthritis, Recombinant Protein for Osteoporosis and Rheumatoid Arthritis, Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis, Recombinant Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia, romosozumab, RPH-203, S-0071500, S-008399, S-101479, SI-000513, Small Molecule for Oncology, Psoriasis and Osteoporosis, Small Molecule for Osteoporosis, Small Molecule to Activate sGC for Osteoporosis, Small Molecule to Agonize Androgen Receptor for Osteoporosis, Small Molecule to Agonize EP4 Receptor for Osteoporosis, Small Molecule to Agonize LRP for Osteoporosis, Small Molecule to Agonize PTH-1R for Osteoporosis, Small Molecule to Antagonize OGR1 for Asthma, Bone Diseases, Oncology and Osteoporosis, Small Molecule to Inhibit 17beta-HSD2 for Osteoporosis, Small Molecule to Target GPR183 for Epstein-Barr Viral Infections and Osteoporosis, Small Molecule to Target LGR4 for Oncology and Osteoporosis, Small Molecule to Target Plexin-B1/Sema4D for Multiple Sclerosis and Osteoporosis, Small Molecules for Metabolic and Musculoskeletal Disorders, Small Molecules for Musculoskeletal and Metabolic Disorders, Small Molecules for Osteopenia and Osteoporosis, Small Molecules for Osteoporosis, Small Molecules to Antagonize Calcium-Sensing Receptor for Osteoporosis, Small Molecules to Inhibit 17Beta-HSD2 for Osteoporosis, Small Molecules to Inhibit GGDPS for Bone Metastasis and Oncology, Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology, Small Molecules to Inhibit Sclerostin for Osteoporosis, Small Molecules to Target Estrogen Receptor for Breast Cancer and Osteoporosis, Sodium Quinate, SP-35454, SR-10171, SR-2595, Synthetic Peptide for Obesity and Post Menopausal Osteoporosis, Synthetic Peptide for Osteoporosis, Synthetic Peptide for Osteoporosis and Bone Fracture, Synthetic Peptides for Ischemic Stroke, Osteoporosis and Sepsis, TE-3110, TE-3236, teriparatide, teriparatide biosimilar, UCB-1, Vaccine to Target Sclerostin for Osteoporosis, VK-5211 and VS-105.

The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 5, 5, 11, 57, 11 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 10 and 13 molecules, respectively.

Scope of this report: The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders). The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders).

This research report will help you to:-

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

LEAVE A REPLY

Please enter your comment!
Please enter your name here